• Pharvaris recently announced that six abstracts featuring its lead candidate deucrictibant for hereditary angioedema, including first-time pivotal Phase 3 RAPIDe-3 data and final Phase 2 CHAPTER-1 results, were accepted for poster presentation at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting.
• This wave of data disclosures, spanning on-demand treatment, prophylaxis, and an extended-release tablet formulation, concentrates investor attention on Pharvaris’s effort to build an oral treatment platform for bradykinin-mediated angioedema.
• We will now examine how the impending presentation of pivotal RAPIDe-3 Phase 3 data shapes Pharvaris’s broader investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Pharvaris' Investment Narrative?

To own Pharvaris, you really have to believe in deucrictibant as a differentiated oral franchise in hereditary angioedema and in management’s ability to convert late‑stage data into approvals without rupturing the balance sheet. The new wave of RAPIDe‑3, CHAPTER‑1, and extended‑release tablet data at AAAAI 2026 slots directly into that thesis, sharpening the near‑term catalyst stack around the planned 2026 NDA for on‑demand treatment and the later CHAPTER‑3 readout in prophylaxis. Given the stock’s strong 1‑ and 3‑year returns and elevated price‑to‑book, the poster acceptances themselves may not be a fundamental game‑changer, but they do reinforce the sense that Pharvaris is entering a “data heavy” period where sentiment can swing quickly. Against zero revenue, widening losses, past dilution and ongoing cash burn, that cuts both ways for shareholders.

However, there is a less obvious financing and dilution risk here that investors should really understand. Despite retreating, Pharvaris' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

The single Simply Wall St Community fair value estimate sits at US$46.33, well above recent trading, yet it is just one private investor’s view. Set that against Pharvaris’s lack of revenue, persistent losses and upcoming clinical and regulatory catalysts, and you can see why opinions on the stock’s longer term performance can understandably diverge.

Explore another fair value estimate on Pharvaris - why the stock might be worth just $46.33!

Build Your Own Pharvaris Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Pharvaris research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pharvaris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pharvaris' overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.